ABSTRACT
AIMS: To survey antibiotic susceptibility of bacteria causing cattle and pig respiratory infections in 10 European countries. METHODS AND RESULTS: Non-replicate nasopharyngeal/nasal or lung swabs were collected from animals with acute respiratory signs during 2015-2016. Pasteurella multocida, Mannheimia haemolytica, Histophilus somni from cattle (n = 281), and P. multocida, Actinobacillus pleuropneumoniae, Glaesserella parasuis, Bordetella bronchiseptica, and Streptococcus suis from pigs (n = 593) were isolated. MICs were assessed following CLSI standards and interpreted using veterinary breakpoints where available. Histophilus somni isolates were fully antibiotic susceptible. Bovine P. multocida and M. haemolytica were susceptible to all antibiotics, except tetracycline (11.6%-17.6% resistance). Low macrolide and spectinomycin resistance was observed for P. multocida and M. haemolytica (1.3%-8.8%). Similar susceptibility was observed in pigs, where breakpoints are available. Resistance in P. multocida, A. pleuropneumoniae, and S. suis to ceftiofur, enrofloxacin, and florfenicol was absent or <5%. Tetracycline resistance varied from 10.6% to 21.3%, but was 82.4% in S. suis. Overall multidrug-resistance was low. Antibiotic resistance in 2015-2016 remained similar as in 2009-2012. CONCLUSIONS: Low antibiotic resistance was observed among respiratory tract pathogens, except for tetracycline.
Subject(s)
Cattle Diseases , Pasteurella multocida , Respiratory Tract Infections , Cattle , Animals , Swine , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacteria , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/veterinary , Respiratory Tract Infections/microbiology , Tetracycline , Respiratory System , Microbial Sensitivity Tests , Cattle Diseases/microbiology , Drug Resistance, BacterialABSTRACT
Mycoplasma hyorhinis is an emerging swine pathogen bacterium causing polyserositis and polyarthritis in weaners and finishers. The pathogen is distributed world-wide, generating significant economic losses. No commercially available vaccine is available in Europe. Therefore, besides improving the housing conditions for prevention, antimicrobial therapy of the diseased animals is the only option to control the infection. Our aim was to determine the minimal inhibitory concentrations (MIC) of ten antimicrobials potentially used against M. hyorhinis infection. The antibiotic susceptibility of 76 M. hyorhinis isolates from Belgium, Germany, Hungary, Italy and Poland collected between 2019 and 2021 was determined by broth micro-dilution method and mismatch amplification mutation assay (MAMA). Low concentrations of tiamulin (MIC90 0.312 µg/ml), doxycycline (MIC90 0.078 µg/ml), oxytetracycline (MIC90 0.25 µg/ml), florfenicol (MIC90 2 µg/ml) and moderate concentrations of enrofloxacin (MIC90 1.25 µg/ml) inhibited the growth of the isolates. For the tested macrolides and lincomycin, a bimodal MIC pattern was observed (MIC90 >64 µg/ml for lincomycin, tulathromycin, tylosin and tilmicosin and 5 µg/ml for tylvalosin). The results of the MAMA assay were in line with the conventional method with three exceptions. Based on our statistical analyses, significant differences in MIC values of tiamulin and doxycycline were observed between certain countries. Our results show various levels of antimicrobial susceptibility among M. hyorhinis isolates to the tested antibiotics. The data underline the importance of susceptibility monitoring on pan-European level and provides essential information for proper antibiotic choice in therapy.
Subject(s)
Anti-Infective Agents , Mycoplasma Infections , Mycoplasma hyorhinis , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/pharmacology , Doxycycline/pharmacology , Europe , Lincomycin/pharmacology , Microbial Sensitivity Tests , Mycoplasma Infections/drug therapy , Mycoplasma Infections/microbiologyABSTRACT
BACKGROUND: Despite the known benefits of active learning (AL), the predominate educational format in higher education is the lecture. The reasons for slow adaptation of AL in medical education are not well understood. The purpose of this survey was to determine knowledge, usage, attitudes, and barriers to AL use in academic Continuing Medical Education (CME). METHOD: A 20-item questionnaire was developed and sent with a link to an online questionnaire to the Society of Academic Continuing Medical Education (SACME) listserv of ~ 350 professionals representing academic medical centers, teaching hospitals, and medical specialty societies in the United States (U.S.) and Canada. Responses were collected with SurveyMonkey® from October-November, 2019. Data were analyzed using SPSS®. RESULTS: Responses from 146 SACME members in 91 CME units yielded a ~ 42% survey response rate. Many respondents reported their self-perceived knowledge of AL as high. Advanced training (e.g., certificate, Master of Education degree) was positively correlated with AL knowledge. AL methods were reportedly used in half of the CME activities in the majority (80%) of institutions. Higher levels of self-perceived knowledge were correlated with an increased percentage of AL-related CME activities. Commonly perceived barriers to use of AL were presenters' lack of familiarity and a need for more time-consuming preparation. CONCLUSIONS: More efforts are needed to increase innovation and incorporate evidence-based AL strategies in medical education, especially to foster learner engagement, critical thinking, and problem-solving ability.
Subject(s)
Education, Medical, Continuing , Problem-Based Learning , Canada , Hospitals, Teaching , Humans , Societies, Medical , United StatesABSTRACT
Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia, a chronic respiratory disease, causing significant economic losses. Results from the 2015-2016 MycoPath pan-European antimicrobial susceptibility monitoring survey of M. hyopneumoniae are presented. In total, 147 M. hyopneumoniae porcine isolates from Belgium, France, Germany, Great Britain, Hungary, Italy, and Spain were tested. One isolate per farm was retained from pigs that had not been recently treated with antimicrobial agents. The minimal inhibitory concentration (MIC) of 13 antimicrobial agents was determined in a central laboratory using a broth microdilution method, with Friis Medium, incubated at 35 ± 1 °C for 5-12 days. M. hyopneumoniae NCTC 10110 was used as Quality Control. MIC50/MIC90 (mg/L) values were: enrofloxacin 0.06/1; marbofloxacin 0.06/2; spiramycin 0.06/0.25; tulathromycin ≤0.001/0.004; gamithromycin 0.06/0.5; tylosin 0.016/0.06; tilmicosin 0.06/0.5; florfenicol 0.5/1; doxycycline 0.25/1; oxytetracycline 0.25/2; lincomycin 0.06/0.25; tiamulin 0.016/0.06 and valnemulin ≤0.001/0.004. Compared with the data from 2010 to 2012 MycoPath study (50 isolates), MIC50/90 results were similar and the majority were within ± two dilution steps, except for the MIC50 of oxytetracycline which is more than two dilution steps higher in the present study. Between-country comparisons show some differences in the MIC values for the fluoroquinolones, tulathromycin and tylosin, but the limited sample size per country precludes performing meaningful country comparisons for several countries. Standardized laboratory methods and interpretive criteria for MIC testing of veterinary mycoplasmas are clearly needed; there are currently no clinical breakpoints available to facilitate data interpretation and correlation of MICs with in vivo efficacy.
Subject(s)
Anti-Bacterial Agents/pharmacology , Epidemiological Monitoring/veterinary , Mycoplasma Infections/veterinary , Mycoplasma hyopneumoniae/drug effects , Animals , Animals, Domestic/microbiology , Europe/epidemiology , Microbial Sensitivity Tests/methods , Microbial Sensitivity Tests/standards , Mycoplasma Infections/epidemiology , Mycoplasma hyopneumoniae/genetics , Mycoplasma hyopneumoniae/isolation & purification , Swine/microbiologyABSTRACT
Mycoplasma gallisepticum and Mycoplasma synoviae are bacterial pathogens that cause disease in poultry, adversely affecting their health and welfare, and are a financial burden on producers. This manuscript describes the results of the MycoPath project that is the first international antimicrobial susceptibility programme for mycoplasma pathogens isolated from poultry. Improved comparative analysis of minimal inhibitory concentration (MIC) results from participating countries was facilitated by using one laboratory determining all MICs. Chicken and turkey isolates were obtained from France, Germany, Great Britain, Hungary, Italy and Spain during 2014-2016. One isolate per farm was retained. The MIC of seven antimicrobial agents was determined using a broth microdilution method, with Friis Medium (M. gallisepticum) or Modified Chanock's Medium (M. synoviae). Of the 222 isolates recovered, 82 were M. gallisepticum and 130 were M. synoviae. M. gallisepticum MIC50/90 values were 0.12/0.5, 2/8, 0.5/4, 0.12/>64, 0.008/0.062, 0.008/32, 0.062/4â mg/l for doxycycline, enrofloxacin, oxytetracycline, spiramycin, tiamulin, tilmicosin and tylosin, respectively. For M. synoviae, the values were 0.5/1, 8/16, 0.5/1, 0.5/8, 0.25/0.5, 0.062/2 and 0.062/16â mg/l respectively. A bimodal MIC distribution for the fluoroquinolone (enrofloxacin) and the macrolides (spiramycin, tilmicosin and tylosin) indicate that both species have sub-populations that are less susceptible in vitro to those antimicrobials. Some differences in susceptibilities were observed according to host species, Mycoplasma species, and country of origin. This study provides a baseline of novel data for future monitoring of antimicrobial resistance in poultry Mycoplasma species. Additionally, this information will facilitate the selection of the antimicrobial agents most likely to be effective, thus ensuring their minimal use with targeted and correct therapeutic treatments.Highlights First large-scale pan-European collection of representative Mg and Ms isolates.MIC values assessed in central laboratory for Mg and Ms from chickens and turkeys.Range of MIC values for 82 Mg and 130 Ms isolates to seven licenced antibiotics shown.Data can be used to help determine Mg and Ms veterinary-specific breakpoints.
Subject(s)
Anti-Infective Agents/pharmacology , Chickens/microbiology , Mycoplasma Infections/veterinary , Mycoplasma gallisepticum/drug effects , Mycoplasma synoviae/drug effects , Poultry Diseases/microbiology , Turkeys/microbiology , Animals , Drug Resistance, Bacterial , Europe , Fluoroquinolones/pharmacology , Macrolides/pharmacology , Microbial Sensitivity Tests/veterinary , Mycoplasma Infections/microbiology , PoultryABSTRACT
OBJECTIVE: In 2008, the Child Health Protection Act (Kindergesundheitsschutz-Gesetz) became effective in Hesse. Since then, participation in the early screening examinations U1 to U9 in Hesse is obligatory. The implementation of the law is part of the responsibility of the Hessian Children's Preventive Healthcare Centre (Hessisches Kindervorsorgezentrum (HKVZ)), which invites parents and legal guardians to each examination from U4 up to and including U9. To obtain information on the acceptance of the law, the HKVZ carried out for the first time a survey of parents and legal guardians as part of their quality management. The following questions were raised: How well accepted are obligatory check-ups by Hessian parents? What is the degree of popularity and the limitation of such a law? METHOD: Along with the letter of invitation to participate in U7a, all parents and legal guardians received an anonymous survey questionnaire to be filled out and returned to the HKVZ. The evaluation took place in the HKVZ. RESULTS: Especially noteworthy are 3 results of the survey: When asked if health problems were detected during the check-ups, 8.94% of the parents and legal guardians answered the question with a "yes". Almost every ninth child examined was found to have health problems during the check-up. The reasons for a missed check-up were comparatively trivial. 96.53% of the respondents had not missed a check-up, only 2.88% answered this question with a "yes" and 0.59% did not give any information here. The most frequent reason for a missed examination with 1.59% was that it was simply "forgotten". In the category "other", 1.12% mentioned a disease of the child or a stay abroad as the most frequent reason for a missed check-up. Difficulty in making an appointment with the pediatrician (0.35% was another reason. The high level of awareness of the Hessian Child Health Protection Act (94.12% of respondents) and the positive ratings of the letters sent by the HKVZ (84.06% good to very good) reflect its acceptance. Further research is needed to confirm the effectiveness of such preventive health care examinations.
Subject(s)
Child Health , Parents , Child , Family , Germany , Humans , Surveys and QuestionnairesABSTRACT
Mycoplasma bovis is an important respiratory pathogen of cattle across Europe and is included in the MycoPath pan-European antimicrobial susceptibility monitoring programme. M. bovis strains (232) were isolated from cattle, not recently treated with antimicrobials, at diverse geographical locations in France, Great Britain, Hungary, Italy and Spain during 2014 to 2016. Only one isolate per farm and per outbreak was retained. For each isolate, the MICs of ten antimicrobials were determined in a central laboratory using a broth microdilution method with modified Eaton's medium and incubation at 35 °C ± 1 °C for 24 ± 6 h. MIC50/MIC90 (mg/L) values for the 232 strains were: danofloxacin 0.25/1; enrofloxacin 0.5/8; marbofloxacin 1/4; gamithromycin >64/>64; spiramycin 8/16; tilmicosin >64/>64; tulathromycin >64/>64; tylosin 64/>64; florfenicol 4/8; oxytetracycline 8/32. Minor between-country differences in the MIC90 values were observed for the fluoroquinolones, spiramycin and oxytetracycline, whilst the MIC values for the other compounds were similar. Spain and Italy had the higher MIC90 values for the fluoroquinolones. Compared with the 2010-2012 study (156 isolates) results are similar, with an overall MIC50 increase of at most one doubling dilution for enrofloxacin, spiramycin, tylosin, florfenicol and oxytetracycline. In contrast, the MIC90 value for oxytetracycline decreased from >64 to 32 mg/L. Standardized laboratory methods and interpretive criteria for MIC testing of veterinary mycoplasmas are clearly needed; there are currently no clinical breakpoints available to facilitate data interpretation and correlation of MICs with in vivo efficacy.
Subject(s)
Anti-Bacterial Agents/pharmacology , Mycoplasma bovis/drug effects , Drug Resistance, Bacterial , Europe , Inhibitory Concentration 50 , Microbial Sensitivity Tests , Mycoplasma bovis/isolation & purificationABSTRACT
BACKGROUND: Lawsonia intracellularis is an obligate intracellular bacterium which cannot be cultured by conventional bacteriological methods. Furthermore, L. intracellularis needs enriched medium and a unique atmosphere for isolation, cultivation and propagation. Because of this,there are only a few isolates of L. intracellularis available and few studies in vitro demonstrating the susceptibility of this bacterium to antimicrobial agents. The objectives of this study were to isolate South American and Southeast Asia strains of L.intracellularis and to determine the in vitro antimicrobial activity against these isolates. Tested antimicrobials included: chlortetracycline, lincomycin, tiamulin, tylosin and valnemulin(against both Brazilian and Thailand strains) and additionally, amoxicillin, zinc-bacitracin, carbadox, enrofloxacin, gentamicin, sulfamethazine, trimethoprim, spectinomycin and a combination (1:1) of spectinomycin and lincomycin were also tested against the Thai isolates. The minimum inhibitory concentration (MIC) was determined by the antimicrobial activity that inhibited 99% of L. intracellularis growth in a cell culture as compared to the control (antimicrobial-free). RESULTS: Two strains from Brazil and three strains from Thailand were successfully isolated and established in cell culture. Each antimicrobial was evaluated for intracellular and extracellular activity. Pleuromutilin group (valnemulin and tiamulin) and carbadox were the most active against L. intracellularis strains tested. Tylosin showed intermediate activity, chlortetracycline had variable results between low and intermediate activity, as well as spectinomycin, spectinomycin and lincomycin, amoxicillin, sulfamethazine and enrofloxacin. L. intracellularis was resistant to lincomycin, gentamicin, trimethoprim, colistin and bacitracin in in vitro conditions. CONCLUSIONS: This is the first report of isolation of L. intracellularis strains from South America and Southeast Asia and characterization of the antimicrobial susceptibility patterns of these new strains.
Subject(s)
Anti-Bacterial Agents/pharmacology , Desulfovibrionaceae Infections/veterinary , Lawsonia Bacteria/drug effects , Swine Diseases/microbiology , Animals , Brazil , Desulfovibrionaceae Infections/microbiology , Lawsonia Bacteria/isolation & purification , Microbial Sensitivity Tests , Swine , ThailandABSTRACT
Mycoplasma hyopneumoniae in pigs and Mycoplasma bovis in cattle are major pathogens affecting livestock across Europe and are the focus of the MycoPath pan-European antimicrobial susceptibility monitoring programme. Fifty M. hyopneumoniae isolates from Belgium, Spain and the United Kingdom (UK), and 156 M. bovis isolates from France, Hungary, Spain and the UK that met specific criteria were tested for antimicrobial susceptibility in a central laboratory by using a microbroth dilution method. Specific isolate criteria included recovery from animals not recently treated with antimicrobials, isolates from different locations within each country and retaining only one isolate per farm. MIC50/MIC90 values were 0.031/0.5, 0.031/0.5, 0.062/0.25, ≤0.001/0.004, 0.031/0.125, 0.25/0.5 and 0.062/0.25mg/L for enrofloxacin, marbofloxacin, spiramycin, tulathromycin, tylosin, florfenicol and oxytetracycline respectively against M. hyopneumoniae and 0.25/4, 1/4, 4/16, >64/ >64, 32/ >64, 2/4 and 4/64mg/L, respectively against M. bovis. MIC50/MIC90 values for tiamulin and valnemulin against M. hyopneumoniae were 0.016/0.062 and ≤0.001/ ≤0.001mg/L respectively. The MIC50/MIC90 values of danofloxacin and gamithromycin for M. bovis were 0.25/1 and >64/ >64mg/L respectively. The highest MIC90 values for M. hyopneumoniae were found in the UK at 1.0mg/L for enrofloxacin, marbofloxacin and florfenicol. In contrast, for M. bovis the lowest MIC90 value was 1.0mg/L, but ranged to >64mg/L. Specific laboratory standards and clinical breakpoints for veterinary Mycoplasma species are required as no independently validated clinical breakpoints are specified for veterinary Mycoplasma species, which makes data interpretation and correlation to in vivo efficacy difficult.
Subject(s)
Anti-Bacterial Agents/pharmacology , Cattle Diseases/microbiology , Drug Resistance, Bacterial , Mycoplasma Infections/veterinary , Mycoplasma bovis , Mycoplasma hyopneumoniae , Swine Diseases/microbiology , Animals , Cattle , Cattle Diseases/epidemiology , Europe/epidemiology , Mycoplasma Infections/epidemiology , Mycoplasma Infections/microbiology , Swine , Swine Diseases/epidemiologyABSTRACT
ComPath is a pan-European antimicrobial surveillance program collecting bacterial pathogens from dogs and cats not recently exposed to antimicrobials. We present minimum inhibitory concentration data obtained using Clinical and Laboratory Standards Institute methodology for 616 urinary tract infection (UTI) isolates collected between 2008 and 2010. In both dogs and cats, the most common pathogen was Escherichia coli (59.8% and 46.7%, respectively). Antimicrobial activity against E. coli in dogs and cats was similar with fluoroquinolone and trimethoprim/sulfamethoxazole susceptibility >90%. Ampicillin susceptibility was â¼80%. Staphylococcus intermedius Group isolates from dogs (67/437, 15.3%) had high antimicrobial susceptibility (>90%) toward beta-lactams, fluoroquinolones, and trimethoprim/sulfamethoxazole. Four canine isolates (6%) were oxacillin resistant, and harbored mecA. Proteus mirabilis from dogs (48/437, 11.0%) had high antimicrobial susceptibility (â¼90%) to amoxicillin/clavulanic acid, enrofloxacin, and marbofloxacin and slightly lower susceptibility (â¼80-85%) to ampicillin and orbifloxacin. Streptococcus canis isolates (35/437, 8.0%) from dogs were all susceptible to ampicillin and amoxicillin/clavulanic acid and >90% susceptible to marbofloxacin. Although resistance was not observed, high intermediate susceptibility was seen for both enrofloxacin (28.6%) and orbifloxacin (85.7%). Overall, antimicrobial in vitro activity appears to be high in UTI pathogens from dogs and cats with low multidrug resistance, although a lack of specific dog and cat breakpoints for important antimicrobials such as cefovecin, cephalexin, and ibafloxacin prevents analysis of susceptibility for these agents.
Subject(s)
Anti-Bacterial Agents/pharmacology , Cat Diseases/drug therapy , Cat Diseases/microbiology , Dog Diseases/drug therapy , Dog Diseases/microbiology , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Animals , Cats , Dogs , Drug Resistance, Bacterial/drug effects , Escherichia coli/drug effects , Europe , Microbial Sensitivity Tests/methods , Proteus mirabilis/drug effects , Staphylococcus intermedius/drug effectsABSTRACT
Stevens-Johnson syndrome (SJS) is a rare condition, characterized by its dramatic involvement of the skin and various mucosal surfaces including the oral mucosae, that severely impairs the affected patient's ability to speak, chew, or swallow. The purpose of this report was to present two cases with significant variations in the clinical presentation of Stevens-Johnson syndrome. In both situations, the patients' conditions were not immediately recognized. Pediatric dentists should be aware of these variations in the clinical manifestations of SJS, as the signs and symptoms can initially mimic common viral conditions. Appropriate diagnosis can result in timely referral to a hospital environment, optimizing patient management and recovery.
Subject(s)
Stevens-Johnson Syndrome/pathology , Adolescent , Child , Humans , Lip/pathology , Male , Mouth/pathology , Oral Ulcer/etiology , Oral Ulcer/pathology , Stevens-Johnson Syndrome/diagnosis , Tongue/pathologyABSTRACT
PURPOSE: Determine the prevalence of pyramidal molars (PMs), associated tooth anomalies, and medical conditions (MC). METHODS: Pantomograms from 10,168 subjects were searched for PMs. RESULTS: A total of 148 individuals (75.7 percent females), aged 9.7 to 18.9 years old, had PMs. Subjects with MCs (53.4 percent) had on average 17 percent more PMs (P=.0476) and 2.8 times greater odds of palatally displaced canines (P=.0309). The mean number of pyramidal and taurodont molars per subject was 2.9±1.4 (SD) and 3.1±1.7 (SD), respectively. In both sexes, 63.5 percent of all observed PMs were located in the maxilla and 78.5 percent of all PMs were second molars. Taurodont molars increased by 9.4 percent as other tooth anomalies increased by one, but decreased by 8.2 percent for each additional PM. Tooth anomalies associated with PMs were palatally displaced canines (17.6 percent) and short root anomaly of maxillary central incisors (6.1 percent). Delayed eruption was noted in 9.5 percent, tooth agenesis in 6.1 percent, and supernumerary teeth in 3.4 percent. CONCLUSIONS: The prevalence of pyramidal molars was 1.4 percent, and the female-to-male ratio was 3.1 to one. Pyramidal molars are often associated with medical conditions and other tooth anomalies.
Subject(s)
Dental Pulp Cavity/abnormalities , Molar/abnormalities , Tooth Abnormalities/epidemiology , Adolescent , Child , Dental Pulp Cavity/diagnostic imaging , Female , Humans , Male , Prevalence , Radiography, Panoramic , Sex Factors , Tooth Abnormalities/diagnostic imagingABSTRACT
ComPath is a pan-European resistance monitoring programme collecting bacterial pathogens from dogs and cats. We present data for respiratory tract infection (RTI) isolates collected between 2008 and 2010. Antimicrobial minimal inhibitory concentrations (MICs) were determined and susceptibility calculated following Clinical Laboratory Standards Institute (CLSI) standards for veterinary medicine. The main pathogen from dogs was Staphylococcus intermedius Group (49/215, 22.8%) which was >90% susceptible to most antimicrobials (including oxacillin - 93.9%; 3 isolates confirmed mecA-positive) but only 59.2%, 73.5% and 87.8% susceptible to tetracycline, chloramphenicol and penicillin. Bordetella bronchiseptica (48/215, 22.3%), streptococci (36/215, 16.7%), Escherichia coli (24/215, 11.2%) and Pasteurella multocida (23/215, 10.7%) were also found in dog RTI. There are no breakpoints for Bordetella bronchiseptica. Most streptococci were penicillin- chloramphenicol-, ampicillin- and pradofloxacin-susceptible. None were enrofloxacin-resistant but 6 isolates (16.7%) were of intermediate susceptibility. The least active agent against streptococci was tetracycline (47.2% susceptible). For E. coli, 37.5% were ampicillin-susceptible but 83.3% were amoxicillin/clavulanic acid-susceptible. Only chloramphenicol showed susceptibility>90% against E. coli, with 66.7% tetracycline-susceptible and 79.2% to 87.5% susceptibility to enrofloxacin, trimethoprim-sulfamethoxazole or pradofloxacin. P. multocida were susceptible to pradofloxacin (no other breakpoints are available). The main pathogen from cats was P. multocida (82/186, 44.1%), where only pradofloxacin has breakpoints (100% susceptible). Streptococci were also collected from cats (25/186, 13.4%) and were >90% susceptible to all antimicrobials except tetracycline (36% susceptible). Most susceptibility was calculated with human-derived breakpoints and some antimicrobials had no breakpoints. Therefore predictions of clinical utility for dog and cat RTI will remain problematical unless specific breakpoints are set.
Subject(s)
Anti-Infective Agents/pharmacology , Bacteria/drug effects , Bacteria/isolation & purification , Cat Diseases/microbiology , Dog Diseases/microbiology , Respiratory Tract Infections/veterinary , Animals , Cats , Dogs , Drug Resistance, Bacterial , Europe , Microbial Sensitivity Tests , Respiratory Tract Infections/microbiologyABSTRACT
PURPOSE: The purpose of this study was to determine, from a large number of panoramic images taken in the clinic of a pediatric dentistry residency program, the prevalence of maxillary nine-year molars (9YM), associated medical conditions (MCs), and the presence of coexisting tooth anomalies (TAs). METHODS: Pantomograms from 13,140 patients were searched for 9YM. Radiographs from identified subjects were examined for coexisting TAs, and charted MCs were noted. For identified 9YM, Nolla's stage of tooth formation was determined and the subjects' dental ages were calculated. RESULTS: Among 53 subjects (68 percent females), 21 unilateral and 32 bilateral cases of 9YM occurred. Females and males were of similar age (7.98 versus 7.91 years old). Overall dental and chronological ages were significantly different: dental development in bilateral cases was delayed by 4.1 months in females and 2.9 months in both sexes (P=.003). In unilateral cases, it was accelerated by 3.6 months in females and 3.5 months in males. The specific tooth age for all 9YM was 4.95 years for females and 5.56 years for males (P=.018). The average count of associated findings (e.g., missing teeth, peg laterals, other TAs, and other eruption delays) was 0.62 in unilateral and 1.44 in bilateral cases (P=.02). Commonly associated MCs included clefting (N equals five), and Down syndrome (n equals three). CONCLUSIONS: The prevalence of nine-year molars was one in 248 (0.4 percent), and the average delay in dental development was 2.7 years.
Subject(s)
Molar/abnormalities , Tooth Abnormalities/epidemiology , Child , Comorbidity , Cross-Sectional Studies , Female , Humans , Male , Maxilla , Molar/diagnostic imaging , Prevalence , Radiography, Panoramic , Tooth Abnormalities/diagnostic imagingABSTRACT
VetPath is an ongoing pan-European antibiotic susceptibility monitoring programme that collects pathogens from diseased cattle, pigs and poultry. In the current study, 996 isolates from cattle and pig respiratory tract infections were tested for their antimicrobial susceptibilities. Non-replicate lung samples or nasopharyngeal/nasal swabs were collected from animals with acute clinical signs in 10 countries during 2009-2012. Pasteurella multocida, Mannheimia haemolytica and Histophilus somni from cattle and P. multocida, Actinobacillus pleuropneumoniae, Haemophilus parasuis, Bordetella bronchiseptica and Streptococcus suis from pigs were isolated by standard methods. S. suis was also isolated from meningitis cases. MIC values of 16 or 17 antibiotics were assessed centrally by broth microdilution following CLSI standards. Results were interpreted using CLSI breakpoints where available. Cattle isolates were generally highly susceptible to most antibiotics, except to tetracycline (3.0-12.0% resistance). Low levels of resistance (0-4.0%) were observed for the macrolide antibiotics. Resistance to spectinomycin varied from 0 to 6.0%. In pig isolates similar observations were made. Resistance to amoxicillin/clavulanic acid, ceftiofur, enrofloxacin, florfenicol, tulathromycin, tiamulin and tilmicosin was absent or <2%. Trimethoprim/sulfamethoxazole resistance varied from 1.9 to 5.3%, but tetracycline resistance varied from 20.4% in P. multocida to 88.1% in S. suis. For most antibiotics and pathogens the percentage resistance remained unchanged or only increased numerically as compared to that of the period 2002-2006. In conclusion, absence or low resistance to antibiotics with defined clinical breakpoints, except for tetracycline, was observed among the major respiratory tract pathogens recovered from livestock. Comparison of all antibiotics and organisms was hampered since for almost half of the antibiotics no CLSI-defined breakpoints were available.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Cattle Diseases/microbiology , Drug Resistance, Bacterial , Respiratory System/microbiology , Respiratory Tract Infections/veterinary , Swine Diseases/microbiology , Animals , Bacterial Infections/microbiology , Bacterial Infections/veterinary , Cattle , Europe , Microbial Sensitivity Tests , Respiratory Tract Infections/microbiology , SwineABSTRACT
PURPOSE: To investigate parents' ability to assess dental anxiety of their six- to 10-year-old children and to determine how parents' and children's fear assessments correlate with patient behavior during dental treatment. METHODS: From a continuous convenience sample, 184 child/parent dyads were recruited to complete the Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) questionnaire prior to dental treatment. One provider treated all children, assessed their behavior, and assigned a Frankl score rating to them. Parent/child anxiety scores were compared to each other and to the behavior children presented during dental treatment. RESULTS: The mean dental anxiety score reported by the children was 30.30; the score reported by their parents was 2.94 points higher (P=.0016). There was poor consistency within parent/child pairs when precisely assessing dental anxiety. Parental assessments of their children's dental anxiety were a poor to fair predictor for observed behavior, whereas the children's self-assessments were fair to good. Child age was not associated with ability to assess anxiety. Parents of children with low anxiety overestimated their children's anxiety, whereas parents of children with high anxiety underestimated their children's anxiety. CONCLUSIONS: Parents and children showed moderate agreement assessing dental anxiety measured by the CFSS-DS. The child's score is preferable for predicting behavior.
Subject(s)
Dental Anxiety , Parents , Child , Child, Preschool , Female , Humans , Male , Surveys and QuestionnairesABSTRACT
UNLABELLED: Dental professionals caring for patients with a diagnosis of autism spectrum disorder (ASD) will need to provide oral health care based on a family-centered approach that involves a comprehensive understanding of parental concerns and preferences, as well as the unique medical management, behaviors, and needs of the individual patient. BACKGROUND: With the rising prevalence of autism spectrum disorders (ASD), oral health providers will find themselves increasingly likely to care for these patients in their daily practice. The purpose of this article is to provide a comprehensive update on the medical and oral health management of patients with autism spectrum disorders. METHODS: The authors conducted a literature review by searching for relevant articles written in English in the PubMed database pertaining to the medical and oral health management of autism, including caries status, preventive, behavioral, trauma, and restorative considerations. CONCLUSIONS: A detailed family centered approach based on parental preferences and concerns, the patient's challenging behaviors, and related comorbidities can serve to improve the treatment planning and oral health management of dental patients with ASD.